Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Randwick Genomics Laboratory, |
RCV001580271 | SCV001809937 | pathogenic | Hermansky-Pudlak syndrome 6 | criteria provided, single submitter | clinical testing | PVS1, PM2, PM3_supporting | |
Invitae | RCV003669242 | SCV004385565 | pathogenic | not provided | 2023-03-26 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with HPS6-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Glu344*) in the HPS6 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 432 amino acid(s) of the HPS6 protein. ClinVar contains an entry for this variant (Variation ID: 1210214). For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the HPS6 protein in which other variant(s) (p.Gln680*) have been determined to be pathogenic (PMID: 27225848, 29054114, 31141302). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. |